癌症相关血栓个体化抗凝治疗：风险评估与精准用药策略

Abstract Cancer-associated thrombosis (CAT) is a common and severe complication in cancer patients, significantly increasing mortality rates and complicating treatment, as well as imposing substantial economic burdens. In recent years, with deeper research into the pathogenesis and risk factors of CAT, individualized anticoagulation therapy strategies have become a focal point in clinical practice. Current research advancements indicate that by integrating clinical risk scoring systems with molecular biomarkers, patient thrombotic risk can be more accurately assessed, thereby guiding the rational selection and dose adjustment of anticoagulant drugs. Additionally, the application of novel oral anticoagulants (DOACs) has provided more convenient and safer options for CAT treatment; however, their efficacy and safety in different patient populations still require further validation. This review summarizes the latest research findings on individualized anticoagulation therapy for CAT, systematically analyzing the advantages and challenges of risk assessment tools and precision medication strategies. The aim is to provide clinical practitioners with scientific and effective treatment guidance to minimize the recurrence of thrombosis and bleeding risks, thereby improving the overall survival quality and living standards of cancer patients. Keywords Cancer-associated thrombosis, individualized treatment, anticoagulation therapy, risk assessment, precision medication